Diabetic Nephropathy - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 214 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 1, 32, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Nephropathy - Overview 8
Diabetic Nephropathy - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Diabetic Nephropathy - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Diabetic Nephropathy - Companies Involved in Therapeutics Development 30
AbbVie Inc 30
Allergan Plc 30
Antisense Therapeutics Ltd 31
Aptevo Therapeutics Inc 31
Araim Pharmaceuticals Inc 32
Arena Pharmaceuticals Inc 32
Astellas Pharma Inc 33
AstraZeneca Plc 33
Bayer AG 34
BLR Bio LLC 34
Boehringer Ingelheim GmbH 35
Cellmid Ltd 35
ChemoCentryx Inc 36
CSL Ltd 36
Daiichi Sankyo Company Ltd 37
DiaMedica Therapeutics Inc 37
Dynamis Therapeutics Inc 38
Galectin Therapeutics Inc 38
GenKyoTex SA 39
Gilead Sciences Inc 39
GNI Group Ltd 40
Islet Sciences Inc 40
Johnson & Johnson 41
MediPost Co Ltd 41
Mesoblast Ltd 42
Mitsubishi Tanabe Pharma Corp 42
MorphoSys AG 43
Noxxon Pharma AG 43
Omeros Corp 44
Paranta Biosciences Ltd 44
PhiloGene Inc 45
PhytoHealth Corp 45
ProMetic Life Sciences Inc 46
Redx Pharma Plc 46
Sarfez Pharmaceuticals Inc 47
Serodus ASA 47
Teijin Pharma Ltd 48
Theravance Biopharma Inc 48
Twoxar Inc 49
Vascular Pharmaceuticals Inc 49
Vicore Pharma AB 49
XORTX Pharma Corp 50
Diabetic Nephropathy - Drug Profiles 51
11-RVIVIT - Drug Profile 51
A-717 - Drug Profile 52
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 53
apararenone - Drug Profile 54
APD-371 - Drug Profile 55
APX-115 - Drug Profile 57
ASP-8232 - Drug Profile 58
atesidorsen sodium - Drug Profile 59
atrasentan hydrochloride - Drug Profile 66
BI-685509 - Drug Profile 68
BI-690517 - Drug Profile 69
BI-703704 - Drug Profile 70
BLR-200 - Drug Profile 71
C-21 - Drug Profile 72
canagliflozin - Drug Profile 75
CCX-140 - Drug Profile 82
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 86
cenicriviroc mesylate - Drug Profile 87
cibinetide - Drug Profile 95
CSL-346 - Drug Profile 98
Cyndacel-M - Drug Profile 99
DM-199 - Drug Profile 101
DM-399 - Drug Profile 106
Drugs for Diabetic Nephropathy - Drug Profile 107
DT-23552 - Drug Profile 108
DYN-12 - Drug Profile 109
emapticap pegol - Drug Profile 111
esaxerenone - Drug Profile 113
finerenone - Drug Profile 116
FM-1302 - Drug Profile 118
GKT-136901 - Drug Profile 119
GKT-831 - Drug Profile 121
GLY-230 - Drug Profile 125
GRMD-02 - Drug Profile 126
GS-444217 - Drug Profile 140
IL-233 - Drug Profile 141
IP-9 - Drug Profile 142
JD-5037 - Drug Profile 143
JNJ-39933673 - Drug Profile 144
MG-132 - Drug Profile 145
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 146
MOR-107 - Drug Profile 148
MPC-300IV - Drug Profile 149
Orbcel-M - Drug Profile 155
PBI-4050 - Drug Profile 156
PBI-4425 - Drug Profile 164
PBI-4547 - Drug Profile 165
PHN-033 - Drug Profile 166
pirfenidone - Drug Profile 167
Recombinant Protein for Diabetic Nephropathy - Drug Profile 169
Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile 170
REDX-06109 - Drug Profile 171
SCO-272 - Drug Profile 172
SER-150 - Drug Profile 173
Small Molecules for Diabetic Nephropathy - Drug Profile 176
Small Molecules to Inhibit AOC3 for Diabetic Nephropathy - Drug Profile 177
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 178
Small Molecules to Inhibit Rho Kinase for Hypertension and Diabetic Nephropathy - Drug Profile 179
SP-20202 - Drug Profile 180
Stem Cell Therapy for Diabetic Nephropathy and Autoimmune Disorders - Drug Profile 181
TBE-31 - Drug Profile 182
TD-0714 - Drug Profile 183
TD-1439 - Drug Profile 185
TMX-049 - Drug Profile 186
TNFR x TWEAKR - Drug Profile 187
VAR-400 - Drug Profile 188
VPI-2690B - Drug Profile 189
VS-105 - Drug Profile 190
Wnt-001 - Drug Profile 191
XRX-108 - Drug Profile 192
XRX-221 - Drug Profile 193
Diabetic Nephropathy - Dormant Projects 194
Diabetic Nephropathy - Discontinued Products 197
Diabetic Nephropathy - Product Development Milestones 198
Featured News & Press Releases 198
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 208
Disclaimer 209

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2017
Diabetic Nephropathy - Pipeline by Allergan Plc, H2 2017
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H2 2017
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2017
Diabetic Nephropathy - Pipeline by Bayer AG, H2 2017
Diabetic Nephropathy - Pipeline by BLR Bio LLC, H2 2017
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Diabetic Nephropathy - Pipeline by Cellmid Ltd, H2 2017
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H2 2017
Diabetic Nephropathy - Pipeline by CSL Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H2 2017
Diabetic Nephropathy - Pipeline by GenKyoTex SA, H2 2017
Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H2 2017
Diabetic Nephropathy - Pipeline by GNI Group Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H2 2017
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2017
Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2017
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2017
Diabetic Nephropathy - Pipeline by Omeros Corp, H2 2017
Diabetic Nephropathy - Pipeline by Paranta Biosciences Ltd, H2 2017
Diabetic Nephropathy - Pipeline by PhiloGene Inc, H2 2017
Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H2 2017
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H2 2017
Diabetic Nephropathy - Pipeline by Redx Pharma Plc, H2 2017
Diabetic Nephropathy - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2017
Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H2 2017
Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H2 2017
Diabetic Nephropathy - Pipeline by Twoxar Inc, H2 2017
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H2 2017
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2017
Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H2 2017
Diabetic Nephropathy - Dormant Projects, H2 2017
Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diabetic Nephropathy - Discontinued Products, H2 2017